NDC 0010-4753-02 - Bio-Mycin 200
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0010-4753
- Requested NDC
- 0010-4753-02
- Package NDCs from labels
- 0010-4753-01, 0010-4753-02, 0010-4753-03
- Manufacturer
- Boehringer Ingelheim Animal Health USA Inc.
- Effective date
- 2025-03-27
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Bio-Mycin® 200 (oxytetracycline injection) | Boehringer Ingelheim Animal Health USA Inc. | 2025-03-27 | PRESCRIPTION ANIMAL DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0010-4753-01 | Bio-Mycin 200 | 100 mL in 1 BOTTLE, GLASS | INJECTION | 100 | 2 | |
| 0010-4753-02 | Bio-Mycin 200 | 250 mL in 1 BOTTLE, GLASS | INJECTION | 250 | 2 | |
| 0010-4753-03 | Bio-Mycin 200 | 500 mL in 1 BOTTLE, GLASS | INJECTION | 500 | 2 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sterile Water | WATER | Baxter Healthcare Corporation | ef3e79c5-3f58-4b36-a296-64b7d9a651c1 | 2017-10-17 | Warnings, Adverse reactions | 059QF0KO0R |
| Eye Wash | WATER | CVS Pharmacy | 049cee29-7ec2-4d5b-8308-f522acde43a7 | 2017-03-29 | Warnings | 059QF0KO0R |
| Sterile Water | WATER | Baxter Healthcare Company | 210dc9ab-d6ca-4552-ac19-1be17792d290 | 2016-05-31 | Warnings, Adverse reactions | 059QF0KO0R |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.